

## AT A GLANCE

**outperforming competition**

- ▶ Unparalleled functional diversity enables optimal lead choice
- ▶ Unlimited applicability to both soluble and cell surface targets

**gold standard therapeutic antibodies**

- ▶ Fully human composition
- ▶ Outstanding intrinsic affinities & potencies – no *in vitro* affinity maturation
- ▶ Excellent manufacturability
- ▶ Rapid discovery timelines, seamless progression into development
- ▶ No target gatekeeping restrictions

## THE SIMPLE ANTIBODY™ PLATFORM

**a transforming force**

*Meeting the demands for blockbuster antibody products requires a unique ability to apply innovative technology to improve upon the commercially proven monoclonal antibody format. arGEN-X is at the forefront of such innovation, playing a transforming role in the human therapeutic antibody space.*

*arGEN-X's business is driven by its **SIMPLE Antibody™** discovery engine: a rich and diverse source of unique antibody candidates with enormous therapeutic potential.*

*Powerful, natural immune responses generate multiple antibody leads of human sequence and structure, bringing unprecedented choice to antibody discovery and maximizing the chances of success in development.*

*The **SIMPLE Antibody™** platform generates antibodies whose intrinsic affinities and potencies avoid the need for *in vitro* affinity maturation. Outstanding expressability, stability and solubility make them ideal candidates as therapeutic products.*

*Antibody discovery using the **SIMPLE Antibody™** platform is rapid and efficient, enabling seamless progression into preclinical development, without the need for additional technologies.*

*The **SIMPLE Antibody™** advantage has been proven in every program conducted to date, yielding functional antibodies against soluble and cell surface targets, including trans-membrane receptors proven intractable with other approaches. arGEN-X is currently developing proprietary antibody programs in inflammation, autoimmune disease and oncology*

**partnering with arGEN-X**

The **SIMPLE Antibody™** Platform is available for partnering to companies seeking outstanding antibody product quality for any target, from an unencumbered technology with proven ability to deliver and succeed

For further discussion of licensing or collaboration opportunities, please contact us at: [business.development@arGEN-X.com](mailto:business.development@arGEN-X.com)

## AT A GLANCE


### intellectual property

- ▶ The SIMPLE Antibody™ Platform is proprietary to arGEN-X. It enjoys long-term patent protection that is independent of other patented technologies in the antibody space.

## THE SIMPLE ANTIBODY™ PLATFORM

### technology

The **SIMPLE Antibody™** platform is based on the surprising discovery that the binding sites of conventional 4-chain antibodies in immunized Camelids have phenomenal functional attributes and comprise sequences and structures that are effectively human.



**SIMPLE: Superior Immunodiversity with Minimal Protein Lead Engineering**

Active immunization of out-bred Camelids with human proteins elicits strong, unrestricted antibody responses. Structural and functional analysis of these antibody responses reveals unprecedented diversity and potency – especially when compared to inbred or transgenic mice. Camelid-derived antibodies have a very high target binding affinity threshold, resulting in impressive biological potency and favorable stability as products.

With minimal engineering, arGEN-X generates antibody product candidates with the closest possible homology to human germline sequence and the ideal human constant region isotype for functional performance.

In summary, arGEN-X is mining a powerful immune system with precision technology, maximising success in antibody drug discovery

#### arGEN-X B.V.

Dr Molewaterplein 50  
3015 GE Rotterdam  
The Netherlands

#### arGEN-X BVBA

Technologiepark 30  
9052 Zwijnaarde  
Belgium

[www.arGEN-X.com](http://www.arGEN-X.com)